Exelixis Clinical Site #9

Yangsan, Gyeongsangnam-do 50612

0 studies enrolling now · 1 studies all time

What they study most

Head and Neck Squamous Cell Carcinoma

Studies at this site

• Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — Running, not enrolling